Riskpilot← Back to searchSign inGet full accessGG Cure Consulting AB
ABActiveOrg 5592422868Jullovsvägen 29Research and experimental development on natural sciences and engineering · NACE 7210Est. 20201 employees
Revenue 2025
SEK 2M
-9% vs 2024
EBITDA margin
77.0%
-9% vs 2024
Equity ratio
91.5%
Financial strength
Net profit 2025
SEK 1,3M
-6% vs 2024
| Revenue | SEK 2M | -9% |
| EBITDA | SEK 1,5M | -9% |
| Net profit | SEK 1,3M | -6% |
| Total assets | SEK 6,2M | +18% |
| Equity | SEK 5,7M | +23% |
| Employees | 1 | — |
Legal name
GG Cure Consulting AB
Org number
5592422868
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
13 februari 2020
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-01-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska, direkt eller indirekt, bedriva konsultverksamhet som medicinsk rådgivare inom läkemedelsindustrin och medicinsk teknik, bedriva läkarpraktik med eget självständigt arbete med undersökning och behandling av patienter, bedriva förvaltning av värdepapper, äga och förvalta fastigheter, äga och förvalta fast och lös egendom, samt därmed förenlig verksamhet.
Address
Jullovsvägen 29
Email
goraneckerwall@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 842 | 1 869 | 1 717 | 2 208 | 2 008 |
| Staff expenses | — | — | −9 | −70 | −90 |
| EBITDA | 1 792 | 1 693 | 1 356 | 1 693 | 1 546 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 1 792 | 1 693 | 1 356 | 1 693 | 1 546 |
| Net financials | — | — | — | 13 | 53 |
| Profit before tax | 1 792 | 1 693 | 1 356 | 1 706 | 1 600 |
| Tax | −384 | −349 | −279 | −353 | −330 |
| Net profit | 1 408 | 1 344 | 1 077 | 1 353 | 1 269 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 267 | 3 373 | 4 623 | 5 294 | 6 239 |
| Equity | 1 433 | 2 599 | 3 489 | 4 646 | 5 712 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 834 | 773 | 1 134 | 648 | 528 |
| Total debt | 834 | 773 | 1 134 | 648 | 528 |
EBITDA margin
77.0%
This company
15.8%
Market median
+387% vs market
20212025
Equity ratio
91.5%
This company
38.2%
Market median
+140% vs market
20212025
Return on equity
22.2%
This company
18.4%
Market median
+21% vs market
20212025
Net profit margin
63.2%
This company
8.1%
Market median
+680% vs market
20212025
Asset turnover
0.32×
This company
1.12×
Market median
-71% vs market
20212025
Debt / equity
0.09×
This company
0.62×
Market median
+85% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-02-01 – 2025-01-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-02-01 – 2024-01-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-02-01 – 2023-01-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-02-01 – 2022-01-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-02-01 – 2021-01-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
CG Chief Executive Officer | Chief Executive Officer | 2022 |
EG Chief Executive Officer | Chief Executive Officer | 2022 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of GG Cure Consulting AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Claes Göran Mikael Eckerwall | Chief Executive Officer | 0 companies |
| Eva Gunilla Eckerwall | Chief Executive Officer | 0 companies |